Tobin Schilke - Jan 31, 2023 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
CFO
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
Jan 31, 2023
Transactions value $
-$110,755
Form type
4
Date filed
2/2/2023, 08:38 PM
Previous filing
Jan 23, 2023
Next filing
Feb 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Sale -$111K -3.2K -5.53% $34.60 54.7K Feb 1, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVNC Employee Stock Option (Right to Buy) Award $0 +50.4K $0.00 50.4K Jan 31, 2023 Common Stock 50.4K $34.68 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke.
F2 Includes 2,953 shares purchased pursuant to the Issuer's 2014 Employee Stock Purchase Plan.
F3 The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from January 31, 2023, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.